IMARA Inc. (IMRA)

$6.32

+0.87 (+15.96%)
Rating:
Recommendation:
-
Symbol IMRA
Price $6.32
Beta 1.081
Volume Avg. 0.12M
Market Cap 165.798M
Shares () -
52 Week Range 0.9739-6.32
1y Target Est -
DCF Unlevered IMRA DCF ->
DCF Levered IMRA LDCF ->
ROE 2.12% Neutral
ROA 1.62% Neutral
Operating Margin -
Debt / Equity 2.03% Neutral
P/E 105.33 Strong Buy
P/B 0.46 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMRA news


Dr. Rahul D. Ballal Ph.D.
Healthcare
Biotechnology
NASDAQ Global Select

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.